Vera Therapeutics, Inc. (VERA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Vera Therapeutics, Inc. (VERA) closed at USD 26.74 on 2026-10-14, a change of -10.7 % over the past year, with a market capitalization of USD 2.06B.

Vera Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vera Therapeutics, Inc. key figures

Previous close

USD 26.74 (2026-10-14)

1-year change

-10.7 %

Market cap

USD 2.06B

Enterprise value

USD 1.64B

P/E ratio (trailing)

-4.87

P/E ratio (forward)

-6.71

EPS (trailing)

-5.87

EPS (forward)

-4.26

PEG ratio

n/a

Price to book

5.04

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.93

Employees

361

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vera Therapeutics, Inc. and compare it with other stocks.